Accuray Reports Impressive Third Quarter Results for Fiscal Year 2025
Accuray Incorporated (NASDAQ: ARAY) has released its financial results for the third quarter of fiscal year 2025, showcasing a significant growth trajectory. During this period, the company reported total net revenues of $113.2 million, reflecting a 12 percent increase year-over-year. This positive growth indicates a robust demand for Accuray’s innovative radiation therapy solutions.
Key Financial Highlights
The results from the third quarter include a net loss of $1.3 million, a remarkable improvement from the $6.3 million loss recorded in the same quarter of the previous year. The adjusted EBITDA surged to $6.0 million, a substantial rise compared to $1.1 million from the prior year.
Revenue Breakdown
Discussing the financial figures further, product revenue increased by 16 percent to reach $57.3 million, up from $49.6 million in the prior year. Service revenue also showed a notable increase, amounting to $55.9 million, compared to $51.5 million in the same quarter last year. This diverse revenue growth illustrates the strength of Accuray's offerings across its product range.
Gross Profit and Operating Expenses
In terms of profitability, total gross profit for the quarter was $31.6 million, which accounted for 27.9 percent of total net revenue. While this figure is an increment from $29.1 million the previous year, it also highlights a slight decrease in percentage terms when compared to last year's 28.7 percent.
Accuray managed to strategically reduce its operating expenses, showing a decrease of 9 percent to $30.6 million from $33.6 million in the previous year. This tight control over costs supports the company’s ongoing efforts to improve profitability.
Guidance and Future Outlook
Looking ahead, Accuray has reaffirmed its adjusted EBITDA guidance for the fiscal year 2025, projecting a range between $28.5 million and $31 million. The overall revenue guidance has been slightly adjusted following recent tariff announcements, now anticipating a total revenue between $452 million and $460 million.
Order Backlog and Operational Performance
The company reported gross product orders in the third quarter decreased to $71.2 million from $89.1 million a year earlier. The book-to-bill ratio also reflected this trend, measured at 1.2 compared to 1.8 in the previous year. As of the end of the quarter, the order backlog stood at $452.4 million, which is around 10 percent lower than the previous year.
As of the end of the quarter, Accuray held cash, cash equivalents, and short-term restricted cash of $78.8 million, representing an increase of $14.8 million from earlier in the fiscal year but a decrease of $9.8 million compared to the end of the previous fiscal year.
CEO Insights on Performance
Suzanne Winter, CEO of Accuray, shared her optimism about the company’s trajectory, stating, “Despite evolving global dynamics, our team's disciplined execution, clear strategy and the growing underlying demand for our innovative technologies give us confidence in our ability to deliver sustained performance.” Her acknowledgment of the team’s resilience underlines the supportive corporate culture that aims to foster growth and innovation.
About Accuray Incorporated
Accuray Incorporated is dedicated to transforming cancer treatment through its advanced radiation therapy technologies. The company focuses on developing innovative solutions designed to meet the diverse needs of patients while enhancing treatment outcomes. Accuray's commitment to continuous innovation reflects its mission to empower clinicians to help patients get back to their lives more effectively and swiftly. Headquartered in Madison, Wisconsin, Accuray operates globally, impacting countless lives with its cutting-edge technologies.
Frequently Asked Questions
What are the recent financial results reported by Accuray?
Accuray reported total net revenues of $113.2 million for the third quarter of fiscal 2025, demonstrating a 12 percent increase year-over-year.
How did Accuray's operating expenses change in the past year?
Operating expenses decreased by 9 percent to $30.6 million, down from $33.6 million in the prior year.
What is the adjusted EBITDA guidance for Accuray for fiscal year 2025?
The adjusted EBITDA is expected in the range of $28.5 million to $31 million for fiscal year 2025.
What is Accuray's current order backlog?
As of the end of the quarter, Accuray's order backlog was $452.4 million, approximately 10 percent lower than the previous year.
What is the main mission of Accuray Incorporated?
Accuray’s mission is to expand the potential of radiation therapy to improve as many lives as possible, delivering unique solutions for complex treatment cases.
